Human genomics technologies in clinical studies – the research landscape: report on the 1990–2024 period

1:1
Published on 14 December, this WHO technical document maps global trends in registered clinical studies using human genomic technologies from 1990 to 2024, including patterns of inclusion and equity.

This WHO snapshot provides a global overview of clinical studies involving human genomic technologies registered between 1990 and 2024. It summarises how research activity has evolved over time and examines patterns in growth, disease focus, geographical distribution and population inclusion, with specific attention to equity of participation. The report is intended to inform stakeholders about the current landscape of genomics in clinical research and where gaps or imbalances may remain.

Year of publication

2025

Source

World Health Organization (WHO) (Technical document; WHO Team: Research for Health (RFH))

Author

WHO Team: Research for Health (RFH)

You might also be interested in

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.